
Mi-Sun Cha
CEO
Built on proprietary technologies and ingredient platforms, MEDIFAB is a global anti-aging company that provides total anti-aging solutions.
MEDIFAB will continue to set new standards in regenerative medicine and medical aesthetics.
Powered by three proprietary platforms, we bring clinical-grade anti-aging from the doctor's office to daily home care.
We pioneer science-driven aesthetics and therapeutics, translating proprietary ingredient platforms into professional-grade anti-aging solutions.
MEDIFAB leverages three proprietary ingredient platforms to deliver total anti-aging performance—from the clinic to the home.
2025
res novae Scalp MD Solution
MFDS approval · FDA registration · EU MDR Class I CE Marking
Approval of clinical trial protocol for Chitosan LTG-S medical device
2024
Launched skin booster res novae Crystal Plus
Launched home-care beauty device res novae Core Impact
2023
Launched res novae brand
Obtained Thailand regulatory approval
2022
Applied for government R&D project
Husteon Nasal MFDS approval
2021
Selected as Innovative Enterprise National Representative 1000
Husteon Mesh MFDS approval
Launched Echrever
2020
Obtained medical device manufacturing license
Obtained Husteon export license
Government-supported R&D project
Obtained ISO 13485 certification
2019
Government-supported R&D project
ISO 9001, ISO 14001 certification
2018
Government-supported R&D project
Venture company certification
2016
Established Medifab corporation
MEDIFAB aims to become a globally recognized leader in medical aesthetics and anti-aging innovation. Grounded in our proprietary ingredient platforms and an expanding network of 50+ partners across Asia, the Middle East, Europe, and North America, we are committed to setting new standards in anti-aging science and bringing the Clinic to Home philosophy to every corner of the world.
A message from
our CEO

CEO
Built on proprietary technologies and ingredient platforms, MEDIFAB is a global anti-aging company that provides total anti-aging solutions.
MEDIFAB will continue to set new standards in regenerative medicine and medical aesthetics.
Global Partners
50+
Asia · Middle East · Europe · N. America
Greater China
3 live sessions with Xu Shan, KRW 1B+
MOU with Shanghai Yanxinuowei
res novae Core Impact initial export to Taiwan (2026)
Japan
res novae Crystal Plus dealership contract completed
Sales commenced in the second half of 2026
Southeast Asia
Local distributor contracts completed in Thailand and Indonesia
Middle East
Exclusive contracts completed in Middle Eastern countries including UAE and Iraq
Sales commenced in the second half of 2026
Europe · Americas
res novae Crystal Plus contract and licensing completed in Canada; sales expansion in the UK